1. Ahoyo TA et al. Prevalence of nosocomial infections and anti-infective therapy in Benin: results of the first nationwide survey in 2012. Antimicrobial resistance and infection control 2014; 3 (1): 1.
2. Petersen MH et al. Incidence and prevalence of hospital-acquired infections in a cohort of patients admitted to medical departments. Dan Med Bull 2010; 57 (11): A4210.
3. Inweregbu K, Dave J, Pittard A. Nosocomial infections. Continuing Education in Anaesthesia. Crit Care Pain 2005; 5 (1): 14–7.
4. Guggenbichler JP et al. Incidence and clinical implication of nosocomial infections associated with implantable biomaterials-catheters, ventilator-associated pneumonia, urinary tract infections. GMS Krankenhaushygiene interdisziplinär 2011; 6 (1).
5. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165 (7): 867–903.
6. Белоусов Ю.Б., Зырянов С.К., Штейнберг Л.Л. Карбапенемы (имипенем, меропенем, дорипенем) в лечении нозокомиальной пневмонии: современное состояние проблемы. Фарматека. 2011; 15 (228). / Belousov Iu.B., Zyrianov S.K., Shteinberg L.L. Karbapenemy (imipenem, meropenem, doripenem) v lechenii nozokomial'noi pnevmonii: sovremennoe sostoianie problemy. Farmateka. 2011; 15 (228). [in Russian]
7. Белоусов Ю.Б., Зырянов С.К., Штейнберг Л.Л. Фармакоэкономические аспекты применения различных карбапенемов (имипенем/циластатин, меропенем, дорипенем) в лечении нозокомиальной пневмонии. Земский врач. 2013; 1. / Belousov Iu.B., Zyrianov S.K., Shteinberg L.L. Farmakoekonomicheskie aspekty primeneniia razlichnykh karbapenemov (imipenem/tsilastatin, meropenem, doripenem) v lechenii nozokomial'noi pnevmonii. Zemskii vrach. 2013; 1. [in Russian]
8. Черний В.И., Колесников А.Н., Лунева А.Г. и др. Новые направления деэскалационной антибактериальной терапии в медицине критических состояний и проблема MRSA-инфекций в отделениях интенсивной терапии. Новости медицины и фармации. Антимикробная терапия. 2010; с. 343. / Chernii V.I., Kolesnikov A.N., Luneva A.G. i dr. Novye napravleniia deeskalatsionnoi antibakterial'noi terapii v meditsine kriticheskikh sostoianii i problema MRSA-infektsii v otdeleniiakh intensivnoi terapii. Novosti meditsiny i farmatsii. Antimikrobnaia terapiia. 2010; s. 343. [in Russian]
9. Галкин Д.В. Карбапенемы через 20 лет после открытия: современные микробиологические и клинические аспекты. Клин. микробиология и антимикробная химиотерапия. 2007; 9 (2). / Galkin D.V. Karbapenemy cherez 20 let posle otkrytiia: sovremennye mikrobiologicheskie i klinicheskie aspekty. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2007; 9 (2). [in Russian]
10. Стецюк О.У. и др. Новый карбапенемный антибиотик дорипенем: перспективы применения в клинической практике. Клин. микробиология и антимикробная химиотерапия. 2008; 10 (3): 245–9. / Stetsiuk O.U. i dr. Novyi karbapenemnyi antibiotik doripenem: perspektivy primeneniia v klinicheskoi praktike. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2008; 10 (3): 245–9. [in Russian]
11. Qu XY, Hu TT, Zhou W. A meta-analysis of efficacy and safety of doripenem for treating bacterial infections. Braz J Infect Dis 2015; 19 (2): 156–62.
12. Богомолова Н.С., Кузнецова С.М., Никода В.В. Дорипенем: микробиологические особенности и клинические аспекты применения у больных нозокомиальной инфекцией (обзор литературы). Фарматека. 2015; 14: 8–18. / Bogomolova N.S., Kuznetsova S.M., Nikoda V.V. Doripenem: mikrobiologicheskie osobennosti i klinicheskie aspekty primeneniia u bol'nykh nozokomial'noi infektsiei (obzor literatury). Farmateka. 2015; 14: 8–18. [in Russian]
13. Инструкция по применению лекарственного препарата для медицинского применения Дорипрекс® (Doriprex®). / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Doripreks® (Doriprex®). [in Russian]
14. Wexler HM et al. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 2005; 49 (10): 4413–7.
15. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S‐4661): a global surveillance report (2003). Clin Microbio Infect 2005; 11 (12): 974–84.
16. Tsuji M et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 1998; 42 (1): 94–9.
17. Pillar CM et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008; 52 (12): 4388–99.
18. Advisory Committee Briefing Book. JNJ-38174942 (Doripenem). NDA 22-171.
19. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004; 48 (4): 1313–9.
20. Sakyo S et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. J Antibiotics 2006; 59 (4): 220–8.
21. Tanimoto K et al. Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob Agents Chemother 2008; 52 (10): 3795–800.
22. Петухова И.Н., Дмитриева Н.В. Роль дорипенема в лечении тяжелых госпитальных инфекций. Эффективная фармакотерапия. 2014; 37: 12–9. / Petukhova I.N., Dmitrieva N.V. Rol' doripenema v lechenii tiazhelykh gospital'nykh infektsii. Effektivnaia farmakoterapiia. 2014; 37: 12–9. [in Russian]
23. Chastre J et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008; 36 (4): 108–96.
24. Horiuchi M et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with b-lactam antibiotics. Toxicology 2006; 222 (1): 114–24.

________________________________________________

1. Ahoyo TA et al. Prevalence of nosocomial infections and anti-infective therapy in Benin: results of the first nationwide survey in 2012. Antimicrobial resistance and infection control 2014; 3 (1): 1.
2. Petersen MH et al. Incidence and prevalence of hospital-acquired infections in a cohort of patients admitted to medical departments. Dan Med Bull 2010; 57 (11): A4210.
3. Inweregbu K, Dave J, Pittard A. Nosocomial infections. Continuing Education in Anaesthesia. Crit Care Pain 2005; 5 (1): 14–7.
4. Guggenbichler JP et al. Incidence and clinical implication of nosocomial infections associated with implantable biomaterials-catheters, ventilator-associated pneumonia, urinary tract infections. GMS Krankenhaushygiene interdisziplinär 2011; 6 (1).
5. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165 (7): 867–903.
6. Belousov Iu.B., Zyrianov S.K., Shteinberg L.L. Karbapenemy (imipenem, meropenem, doripenem) v lechenii nozokomial'noi pnevmonii: sovremennoe sostoianie problemy. Farmateka. 2011; 15 (228). [in Russian]
7. Belousov Iu.B., Zyrianov S.K., Shteinberg L.L. Farmakoekonomicheskie aspekty primeneniia razlichnykh karbapenemov (imipenem/tsilastatin, meropenem, doripenem) v lechenii nozokomial'noi pnevmonii. Zemskii vrach. 2013; 1. [in Russian]
8. Chernii V.I., Kolesnikov A.N., Luneva A.G. i dr. Novye napravleniia deeskalatsionnoi antibakterial'noi terapii v meditsine kriticheskikh sostoianii i problema MRSA-infektsii v otdeleniiakh intensivnoi terapii. Novosti meditsiny i farmatsii. Antimikrobnaia terapiia. 2010; s. 343. [in Russian]
9. Galkin D.V. Karbapenemy cherez 20 let posle otkrytiia: sovremennye mikrobiologicheskie i klinicheskie aspekty. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2007; 9 (2). [in Russian]
10. Stetsiuk O.U. i dr. Novyi karbapenemnyi antibiotik doripenem: perspektivy primeneniia v klinicheskoi praktike. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2008; 10 (3): 245–9. [in Russian]
11. Qu XY, Hu TT, Zhou W. A meta-analysis of efficacy and safety of doripenem for treating bacterial infections. Braz J Infect Dis 2015; 19 (2): 156–62.
12. Bogomolova N.S., Kuznetsova S.M., Nikoda V.V. Doripenem: mikrobiologicheskie osobennosti i klinicheskie aspekty primeneniia u bol'nykh nozokomial'noi infektsiei (obzor literatury). Farmateka. 2015; 14: 8–18. [in Russian]
13. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Doripreks® (Doriprex®). [in Russian]
14. Wexler HM et al. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 2005; 49 (10): 4413–7.
15. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S‐4661): a global surveillance report (2003). Clin Microbio Infect 2005; 11 (12): 974–84.
16. Tsuji M et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 1998; 42 (1): 94–9.
17. Pillar CM et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008; 52 (12): 4388–99.
18. Advisory Committee Briefing Book. JNJ-38174942 (Doripenem). NDA 22-171.
19. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004; 48 (4): 1313–9.
20. Sakyo S et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. J Antibiotics 2006; 59 (4): 220–8.
21. Tanimoto K et al. Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob Agents Chemother 2008; 52 (10): 3795–800.
22. Petukhova I.N., Dmitrieva N.V. Rol' doripenema v lechenii tiazhelykh gospital'nykh infektsii. Effektivnaia farmakoterapiia. 2014; 37: 12–9. [in Russian]
23. Chastre J et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008; 36 (4): 108–96.
24. Horiuchi M et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with b-lactam antibiotics. Toxicology 2006; 222 (1): 114–24.